February 28, 2026, marks Rare Disease Day (RDD), the world’s largest global awareness campaign dedicated to improving understanding of rare diseases and advancing diagnosis, treatment, and quality of life for those affected and their families. Recognizing the importance of this global effort, JCR will once again support RDD 2026 in Japan.
JCR has supported RDD Japan since 2015 and will again participate through awareness and engagement initiatives.
Featured Session at RDD Tokyo event
JCR will present a featured session at the RDD Tokyo event on February 28 (17:30-18:00, scheduled) at KABUTO ONE 4F Hall and Conference floor, 7-1 Nihonbashi Kabutocho, Chuo-ku, Tokyo, Japan.
The session will include a video presentation titled “Sport Connects. Bringing Hope to Rare Diseases” featuring professional tennis players, Masamichi Imamura and Shinji Hazawa, official ambassadors for RDD Japan.
Volunteer Participation
JCR employees will participate in volunteer activities at the Universal Baseball area themed “Move and Play,” where assistive technologies enable children requiring medical care to enjoy sports through finger-controlled digital interaction.
Awareness Display
An educational panel explaining lysosomal storage disorders in a clear and accessible way will be displayed at multiple venues nationwide, including Tokyo Tower FOOT TOWN (2F), the RDD Tokyo venue (KABUTO ONE), the RDD Japan event at Yamaguchi Prefecture, and other official RDD event venues. The panel will also be available via the RDD Japan website.
(URL: https://rddjapan.info/2026/panel/ (in Japanese))
Across the JCR Group, employees support RDD through ongoing awareness initiatives, from displaying posters and wearing official RDD badges to participating in sporting events in company-designed apparel and other outreach activities that help raise awareness of rare diseases. This year, JCR and MEDIPAL HOLDINGS CORPORATION hosted an internal workshop featuring perspectives from patient families, using a Patient Journey Map1 to deepen employee understanding of rare diseases.
The spirit of RDD is a part of who we are at JCR. Alongside advancing R&D to develop new therapies, we remain equally committed to awareness, inclusion, and standing with patients living with rare diseases worldwide.
About Rare Disease Day (RDD)
Rare Disease Day, launched in 2008, has grown into the world’s largest awareness campaign for rare diseases, celebrated in over 100 countries. In Japan, RDD official events have been held since 2010. This year’s theme in Japan highlights Tomo ni, Sugosu. Tomo ni, Tsukuru. Toki ni, Warau.
(Spending time together. Creating together. Laughing sometimes.)
About JCR Pharmaceuticals Co., Ltd.
JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world’s most complex healthcare challenges. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the U.S., Europe, and Latin America. We improve patients’ lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. Our core values – Putting people first, Forging our own path, Always advancing, and Committed to excellence – mean that the work we do benefits all our stakeholders, including partners, patients and employees. We strive to expand the possibilities for patients while accelerating medical advancement at a global level.
References
1: A tool illustrating a patient’s journey through diagnosis and treatment.
Rare Disease Day global website: https://www.rarediseaseday.org/
RDD Japan website: https://rddjapan.info/
Contact:
Investors & Media:
JCR Pharmaceuticals Co., Ltd.
Corporate Communications
ir-info@jp.jcrpharm.com